Therapies / Neurology / Research / Therapeutics / Brain / Drugs / Drug / Gene / Genes / Gene Therapy / Genetics / Boston blog main / Boston top stories / National blog main / National top stories / New York / New York blog main / New York top stories / San Francisco blog main / San Francisco top stories / Acadia Pharmaceuticals / Acorda Therapeutics / Adamas Pharmaceuticals / Alector / Alexion Pharmaceuticals / Asa Abeliovich / Columbia University / deals / dyskinesia / FDA / GBA1 / Jonathan Silverstein / Leonard Bell / Levodopa / Life Sciences / Lysosomal Therapeutics / Michael J. Fox Foundation / National Parkinson Foundation / Neurodegenerative Diseases / OrbiMed Advisors / Parkinson’s Institute and Clinical Center / pimavanserin / Prevail Therapeutics / RegenxBio / Silverstein Foundation / startups / Steve Squinto / VC / Voyager Therapeutics

For Parkinson's, Two Drugs Coming And One New Co as Prevail Starts in NY

Posted on: Aug 9, 2017   |   Posted by: Biotech Mag

For Parkinson's, Two Drugs Coming And One New Co as Prevail Starts in NY

A drug that actually slows or reverses the brain damage inflicted by Parkinson's disease, rather than just alleviates its often debilitating symptoms, remains elusive. But...

Continue reading ...



Other Posts from Biotech Mag